CTRP3 (Human) Globular Form recombinant 00082-01-100 and CTRP3 ELISA Kit SK00082-07 had been used by Dr. Liling Wu on following research.

Zhou Y , and Wu LL. Overexpression of c1q/tumor necrosis factor-related protein-3 promotes phosphate-induced vascular smooth muscle cell calcification both in vivo and in vitro. Arterioscler Thromb Vasc Biol. 2014 May;34(5):1002-10. doi: 10.1161/ ATVBAHA.114.303301. Epub 2014 Feb 27.

Dr. Tan and Dr. Randeva had used human CTRP3 ELISA Kit SK00082-01 on following research report.

Metformin Increases the Novel Adipokine Cartonectin/CTRP3 in Women with Polycystic Ovary Syndrome

Context: Recently cartonectin was reported as a novel adipokine, with lower levels in diet-induced obese mice, glucose-lowering effects, and anti-inflammatory and cardio protective properties. Polycystic ovary syndrome (PCOS) is a proinflammatory state associated with obesity, diabetes, dyslipidemia, and cardiovascular complications.

Objectives: The objective of the study was to investigate cartonectin levels and regulation in sera and adipose tissue (AT) as well as the effects of metformin of women with PCOS and control subjects.

Design: This was a cross-sectional study [PCOS (n = 83) and control (n = 39) subjects]. Real-time PCR and Western blotting were used to assess mRNA and protein expression of cartonectin. Serumcartonectin was measured by an ELISA.

Results: Serum and omental adipose tissue cartonectin were significantly lower in women with PCOS compared with control subjects (P < .05 and P < .01, respectively). Furthermore, cartonectin showed a significant negative association with body mass index, waist to hip ratio, glucose, insulin, total cholesterol, low-density lipoprotein-cholesterol, triglycerides, High sensitivity C-reactive protein (hs-CRP) and intima-media thickness (P < .05 and P < .01, respectively); in multiple regression analyses, triglycerides (P =0.40) and hs-CRP (P = .31) were predictive of cartonectin levels (P < .05). After 6 months of metformin treatment, there was an associated increase in serum cartonectin (P < .05). Importantly, changes in hs-CRP were significantly negatively correlated with changes in serum cartonectin (P = .33). Finally, cartonectinprotein production and secretion into conditioned media were significantly increased by metformin in control human omental AT explants (P < .05).

Conclusions: Serum and omental AT cartonectin are lower in women with PCOS. Metformin treatment increases serum cartonectin levels in these women and in omental AT explants.

Tan BK, et al. J Clin Endocrinol Metab. 2013 Oct 23. [Epub ahead of print]

C1q/TNF-related protein-3 (CTRP3) levels are decreased in obesity and hypertension and are negatively correlated with parameters of insulin resistance.

BACKGROUND: Insulin resistance (IR) correlates closely with cardiovascular disease. C1q/TNF-related protein-3 (CTRP3) is a novel adipokine that modulates insulin activity in various diseases. This study investigated the relationship between CTRP3 and IR as well as systemic inflammation in newly diagnosed obese and hypertensive patients (NCT02226471).

METHODS: Serum CTRP3 levels, anthropometric, inflammatory and metabolic parameters were measured in 180 obesity and essential hypertensive patients and in 66 normal weight, normotensive subjects.

RESULTS: The serum CTRP3 levels in the obesity group were lower than those in the NW group; these levels were also lower in hypertensive subjects than in normotensive subjects. After adjusting for gender, systolic blood pressure (SBP) and diastolic blood pressure (DBP), a modestly linear relationship was observed between CTRP3 and waist circumference (WC) (r = -0.168, p = 0.009), waist-to-hip ratio (WHR) (r = -0.183, p = 0.004), homeostasis model assessment of IR (HOMA-IR) (r = -0.264, p = 0.000), triglycerides (TG) (r = -0.136, p = 0.034), fasting blood glucose (FBG) (r = -0.155, p = 0.016), fasting insulin (FINS) (r = -0.248, p = 0.000) and homeostasis model assessment of β-cell insulin secretion (HOMA-β) (r = -0.128, p = 0.047). Multiple stepwise regression analysis revealed that gender, DBP and HOMA-IR were independently associated with serum CTRP3 levels.

CONCLUSION: CTRP3 was an independent factor affecting blood pressure and IR, and may play an important role in the pathogenesis of obesity and hypertension.

Deng W., et al. Diabetol Metab Syndr. 2015 Apr 10;7:33. doi: 10.1186/s13098-015-0029-0. eCollection 2015.

Adipose tissue-derived adipokines play important roles in controlling systemic insulin sensitivity and energy balance. Our recent efforts to identify novel metabolic mediators produced by adipose tissue have led to the discovery of a highly conserved family of secreted proteins, designated as C1q/TNF-related protein (CTRP)1 to CTRP10. However, physiological functions regulated by CTRPs are largely unknown. Here we provide the first in vivo functional characterization of CTRP3. We show that circulating levels of CTRP3 are inversely correlated with leptin levels: CTRP3 increases with fasting, decreases in diet-induced obese mice with high leptin levels, and increases in leptin-deficient ob/ob mice. A modest three-fold elevation of plasma CTRP3 levels by recombinant protein administration is sufficient to lower glucose levels in normal and insulin-resistant ob/ob mice, without altering insulin or adiponectin levels. The glucose-lowering effect in mice is linked to activation of the Akt signaling pathway in liver and a marked suppression of hepatic gluconeogenic gene expression. Consistent with its effects in mice, CTRP3 acts directly and independently of insulin to regulate gluconeogenesis in cultured hepatocytes. In humans, alternative splicing generates two circulating CTRP3 isoforms differing in size and glycosylation pattern. The two human proteins form hetero-oligomers, an association that does not require inter-disulfide bond formation and appears to protect the longer isoform from proteolytic cleavage. Recombinant human CTRP3 also reduces glucose output in hepatocytes by suppressing gluconeogenic enzyme expression. This study provides the first functional evidence linking CTRP3 to hepatic glucose metabolism and establishes CTRP3 as a novel adipokine.

Peterson JM, Wei Z, Wong GW. J Biol Chem. 2010 Oct 15. [Epub ahead of print]

Name

Catalog Number

Size

Price (USD)

ELISA Kits

CTRP3/Cartonectin (Human) ELISA Kit

SK00082-01

96T

$420.00

CTRP3 (Human) ELISA Kit

SK00082-07

96T

$450.00

Antibody

Anti CTRP3 (Human) Monoclonal lgG

A00082-08-100

100µg

$320.00

Anti CTRP3 (Human) lgG

A00082-01-100

100µg

$220.00

Anti CTRP3 (Human) lgG, Biotinylated

A00082-01-100B

100µg

$360.00

Anti CTRP3 (Human) lgG, FITC conjugated

A00082-01-100F

100µg

$360.00

Anti CTRP3 (Human) lgG, Cy3 conjugated

A00082-01-100C3

100µg

$495.00

Anti CTRP3 (Mouse) lgG

A00082-03-100

100µg

$260.00

Anti CTRP3 (Mouse) lgG, Biotinylated

A00082-03-100B

100µg

$360.00

Anti CTRP3 (Mouse) lgG, FITC conjugated

A00082-03-100F

100µg

$360.00

Anti CTRP3 (Mouse) lgG, Cy3 conjugated

A00082-03-100C3

100µg

$495.00

Recombinant

CTRP3 (Human), Globular Form Recombinant

00082-01-50

50µg

$180.00

CTRP3 (Human), Globular Form Recombinant

00082-01-100

100µg

$295.00

CTRP3 (Human), Globular Form Recombinant

00082-01-1000

1mg

Inquire

CTRP3 (Human), Globular Form Recombinant, Biotinylated

00082-01-50B

50µg

$360.00

CTRP3 (Human), Globular Form Recombinant, Cy3

00082-01-50C3

50µg

$495.00

CTRP3 (Human), Globular Form Recombinant, Cy5

00082-01-50C5

50µg

$495.00

CTRP3 (Human), Globular Form Recombinant, FITC

00082-01-50F

50µg

$450.00

CTRP3 (Mouse), Globular Form Recombinant

00082-03-100

100µg

$295.00

CTRP3 (Mouse), Globular Form Recombinant

00082-03-50

50µg

$195.00

CTRP3 (Human), Full Length Recombinant

00082-04-100

100µg

$360.00

CTRP3 (Human) (46-246) Recombinant

00082-02-100

100µg

$360.00

CTRP3 (Human) (46-116) Recombinant

00082-05-100

100µg

$320.00